Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.43 |
| ▸ | PPARG | P37231 | 7/20 | 0.43 |
| ▸ | PPARD | Q03181 | 7/20 | 0.43 |
| ▸ | PPARA | Q07869 | 7/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TLR2 | O60603 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | FABP4 | P15090 | 2/20 | 0.43 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4649165 | 1.00 | CES2 (0.44) | CES2GPR84PPARGPPARDPPARA | |
| SCHEMBL1704718 | 1.00 | CES2 (0.44) | CES2GPR84PPARGPPARDPPARA | |
| SCHEMBL9932880 | 1.00 | CES2 (0.44) | CES2GPR84PPARGPPARDPPARA | |
| SCHEMBL5879070 | 1.00 | CES2 (0.44) | CES2GPR84PPARGPPARDPPARA | |
| SCHEMBL573735 | 1.00 | CES2 (0.44) | CES2GPR84PPARGPPARDPPARA | |
| SCHEMBL20936468 | 1.00 | CES2 (0.44) | CES2GPR84PPARGPPARDPPARA | |
| SCHEMBL20915491 | 1.00 | CES2 (0.44) | CES2GPR84PPARGPPARDPPARA | |
| SCHEMBL20915417 | 1.00 | CES2 (0.44) | CES2GPR84PPARGPPARDPPARA | |
| SCHEMBL20915246 | 1.00 | CES2 (0.44) | CES2GPR84PPARGPPARDPPARA | |
| Ammonia Solution, Strong SCHEMBL28708430 | 0.98 | CES2 (0.42) | CES2GPR84PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3661600-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME | Epitracker, Inc. (US) | 2020-06-10 | — | — | EP | claimed |
| US-20260048037-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN | EPITRACKER INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12440473-B2 | Fatty acid analogs and their use in the treatment of cognitive impairment, behavioral conditions, and chronic pain | Epitracker, Inc. (US) | 2025-10-14 | — | — | US | disclosed |
| US-11951088-B2 | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome | Epitracker, Inc. (US) | 2024-04-09 | — | — | US | disclosed |
| EP-3934639-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN | Epitracker, Inc. (US) | 2022-01-12 | — | — | EP | disclosed |
| US-20210386710-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN | Epitracker, Inc. | 2021-12-16 | — | — | US | disclosed |
| US-20210386710-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN | Epitracker, Inc. | 2021-12-16 | — | — | US | disclosed |
| US-10792266-B2 | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome | Epitracker, Inc. (US) | 2020-10-06 | — | — | US | disclosed |
| US-10792266-B2 | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome | Epitracker, Inc. (US) | 2020-10-06 | — | — | US | disclosed |
| EP-3661600-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME | Epitracker, Inc. (US) | 2020-06-10 | — | — | EP | disclosed |
| US-20190117607-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME | Epitracker, Inc. | 2019-04-25 | — | — | US | disclosed |
| US-20190117607-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME | Epitracker, Inc. | 2019-04-25 | — | — | US | disclosed |
| US-7533723-B2 | Well bore treatment fluid | SCHLUMBERGER TECHNOLOGY CORPORATION (US) | 2009-05-19 | — | — | US | disclosed |
| US-7533723-B2 | Well bore treatment fluid | SCHLUMBERGER TECHNOLOGY CORPORATION (US) | 2009-05-19 | — | — | US | disclosed |
| US-20070095534-A1 | Well bore treatment fluid | SCHLUMBERGER TECHNOLOGY CORPORATION | 2007-05-03 | — | — | US | disclosed |
| US-20070095534-A1 | Well bore treatment fluid | SCHLUMBERGER TECHNOLOGY CORPORATION | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190117607-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME | FABP1, FASN, GPR119 | CES2 1954/4885GPR84 598/4885PPARG 82/4885 |
| US-20210386710-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN | SCD, FABP7, ELOVL1 | CES2 205/4885GPR84 174/4885PPARG 31/4885 |
| US-10792266-B2 | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome | FABP1, FASN, GPR119 | CES2 1954/4885GPR84 598/4885PPARG 82/4885 |
| US-11951088-B2 | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome | FABP1, FASN, GPR119 | CES2 1954/4885GPR84 598/4885PPARG 82/4885 |
| US-20260048037-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN | CNR1, CNR2, FFAR1 | CES2 133/4885GPR84 168/4885PPARG 4/4885 |
| US-12440473-B2 | Fatty acid analogs and their use in the treatment of cognitive impairment, behavioral conditions, and chronic pain | SCD, FABP7, ELOVL1 | CES2 205/4885GPR84 174/4885PPARG 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.